CorMatrix Names President and Chief Operating Officer

CorMatrix Cardiovascular Inc., a developer of biomaterial compositions and medical devices for regenerative medicine, has appointed Andrew M. Green as president and chief operating officer, and Patrick R. Ferguson as national sales director. Both appointments are effective Jan. 1.

Green will be responsible for the company’s worldwide product lines and operations, reporting to David Camp, CorMatrix’s chairman/CEO. Ferguson is responsibley for U.S. sales and marketing, and reports to Green.

Green joined the company in July 2013 as vice president of Regulatory, Clinical and Quality Affairs; prior to Jan. 1, he served as executive vice president of Operations. He is credited with consolidating CorMatrix’s operations and expediting its product pipeline, including U.S. Food and Drug Administration (FDA) clearance of three new products and the initiation of clinical trials for two product pipelines, while also positioning the business for future growth.

“Drew Green’s 23 years of demonstrated leadership experience in the medical technology industry have prepared him well to assume the expanded responsibilities of his new role,” said Camp. “Since joining CorMatrix, Drew has rapidly gained the organization’s respect as he moved decisively to strengthen the company’s franchise. He also has been involved in a number of corporate initiatives that have given him exposure to various parts of the business and geographic operating entities. I’m extremely pleased to have an executive of Drew’s caliber taking an even greater role in helping to build CorMatrix’s future.”

Before joining CorMatrix, Green held various executive roles in public and private companies including vice president of Regulatory and Clinical Affairs at Halscion Inc.; president and CEO for Oncologix Tech Inc.; principal in NeoMedica LLC; and vice president of Scientific Affairs at Novoste Corporation. He started his career as a scientific reviewer for the FDA, where he reviewed scientific, technical, pre-clinical and clinical data submitted in support of the safety and effectiveness of both interventional and general cardiovascular devices. Green holds a Bachelor of Science degree in biological sciences and an master’s degree in bioengineering, both from Clemson University, where his research focused on characterization and use of materials in a biological environment.

Ferguson joined CorMatrix as an area sales director in November 2012. Bringing more than 18 years of leadership and sales experience, he has been instrumental in delivering strategic vision, culture development, and sales excellence to CorMatrix, executives said. Since joining the company, he served as eastern area director and helped launch the CorMatrix Vascular and Electrophysiology product lines. In addition, Ferguson spent 12 years with Medtronic plc as a district manager and senior sales rep in its CRM division. He has also held sales roles with St. Jude Medical Inc. in itsr CRM division. Ferguson received his Bachelor of Science degree from the University of Florida.

“Patrick has demonstrated success in sales and sales management over the years and especially at CorMatrix. We’re pleased to expand his responsibilities to include direct leadership of our U.S. sales and marketing efforts,” said Green. “We are truly excited about the future growth of CorMatrix and with Patrick’s leadership, we’re already seeing the initial results of his work.”

CorMatrix Cardiovascular Inc. is a privately held medical device developer of biomaterial devices that harness the body’s own innate ability to repair damaged cardiac and vascular tissues. CorMatrix ECM Technology allows surgeons to restore the native anatomy of cardiac and vascular tissue in need of repair, serving as an alternative to synthetic or cross-linked materials. Headquartered in Roswell, Ga., the company is currently researching, developing and commercializing a platform technology known as CorMatrix ECM for a variety of cardiovascular and other indications, and has U.S. clearance and European registration (with a CE Mark) for its ECM technology. Since its launch in 2006, CorMatrix ECM technology has been used at more than 975 hospitals across the United States and has been implanted in more than 135,000 cardiovascular procedures.